Herbas VPB

Print
EN | LT
LT - (1R,5S)-(+)-1-(naftalen-2-il)-3-azabiciklo{3.1.0} heksano naudojimas monoamino neurotransmiterių paveiktoms ligoms gydyti
EN - USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS

Legal status

Patent in force

Claims | Licences/Sublicenses
Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 9/00 (2006.01)
A61P 25/00 (2006.01)
A61K 31/403 (2006.01)
European patent
(11) Number of the document 2819516
(13) Kind of document T
(96) European patent application number 12820058.1
Date of filing the European patent application 2012-07-27
(97) Date of publication of the European application 2015-01-07
(45) Date of publication and mention of the grant of the patent 2019-12-25
(46) Date of publication of the claims translation 2020-05-25
PCT application
(86) Number PCT/US2012/000335
Date 2012-07-27
PCT application publication
(87) Number WO 2013/019271
Date 2013-02-07
Priority applications
(30) Number Date Country code
201161574231 P 2011-07-30 US
201113334066 2011-12-22 US
201213528940 2012-06-21 US
Inventors
(72)
MCKINNEY, Anthony Alexander, US
BYMASTER, Frank, US
Grantee
(73) Otsuka America Pharmaceutical, Inc., 2440 Research Boulevard, Rockville, MD 20850, US
Attorney or representative
(74) Aušra PAKĖNIENĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Title
(54) (1R,5S)-(+)-1-(naftalen-2-il)-3-azabiciklo{3.1.0} heksano naudojimas monoamino neurotransmiterių paveiktoms ligoms gydyti
  USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
Last renewal fee
Payment date Validity (years) Amount
2025-06-18 14 289.00 EUR
Next renewal fee
2026-07-27
Last update date 2025-06-20